Energy metabolism in skin cancers: A therapeutic perspective.
Skin cancers are the most common cancers worldwide. The incidence of common skin cancers, including basal cell carcinomas (BCCs), squamous cell carcinomas (SCCs) and melanomas, continues to rise by 5 to 7% per year, mainly due to ultraviolet (UV) exposure and partly because of aging. This suggests an urgent necessity to improve the level of prevention and protection for skin cancers as well as developing new prognostic and diagnostic markers of skin cancers. Moreover, despite innovative therapies especially in the fields of melanoma and carcinomas, new therapeutic options are needed to bypass resistance to targeted therapies or treatment's side effects. Since reprogramming of cellular metabolism is now considered as a hallmark of cancer, some of the recent findings on the role of energy metabolism in skin cancer initiation and progression as well as its effect on the response to targeted therapies are discussed in this review. This article is part of a Special Issue entitled Mitochondria in cancer, edited by Giuseppe Gasparre, Rodrigue Rossignol and Pierre Sonveaux.
Inserm U 1035, 33076 Bordeaux, France; Université de Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux, France.
Mohsen
M
Hosseini
Inserm U 1035, 33076 Bordeaux, France; Université de Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux, France.
Zeinab
Z
Kasraian
Inserm U 1035, 33076 Bordeaux, France; Université de Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux, France; Centre de Référence pour les Maladies Rares de la Peau, CHU de Bordeaux, France. Electronic address: hamid-reza.rezvani@u-bordeaux.fr.
Hamid Reza
HR
Rezvani
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control; D002455:Cell Division / Q000187:drug effects; D004272:DNA, Mitochondrial / Q000235:genetics; D019008:Drug Resistance, Neoplasm; D004734:Energy Metabolism / Q000187:drug effects; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control; D024101:Mitochondrial Proteins / Q000235:genetics / Q000502:physiology; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D010085:Oxidative Phosphorylation; D015398:Signal Transduction / Q000187:drug effects; D012878:Skin Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000517:prevention & control
D000970:Antineoplastic Agents; D004272:DNA, Mitochondrial; D024101:Mitochondrial Proteins; D009363:Neoplasm Proteins
BCC; Cancer biomarker; Carcinoma; Melanoma; Mitochondria; SCC; Targeted therapy; Warburg effect